Breaking: SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen

In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9. The win for Sanofi and Regeneron is a setback for…

Click to view original post